--- title: "Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296312501.md" description: "Benitec Biopharma (NASDAQ:BNTC) stock crossed above its 50-day moving average, trading at $12.88. Analysts maintain a 'Moderate Buy' consensus with an average price target of $24.80, though ratings vary from 'Outperform' to 'Sell'. Institutional investors have increased holdings, with major firms like Bank of America and BNP Paribas significantly boosting their stakes in recent quarters." datetime: "2026-08-19T06:40:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296312501.md) - [en](https://longbridge.com/en/news/296312501.md) - [zh-HK](https://longbridge.com/zh-HK/news/296312501.md) generator: "portal-rs" --- # Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving Average - Time to Sell? Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report)'s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $12.48 and traded as high as $13.65. Benitec Biopharma shares last traded at $12.88, with a volume of 211,212 shares trading hands. Get **Benitec Biopharma** alerts: ## Wall Street Analyst Weigh In A number of equities research analysts recently weighed in on BNTC shares. Wedbush started coverage on Benitec Biopharma in a report on Tuesday, July 28th. They set an "outperform" rating and a $16.00 price target for the company. Evercore assumed coverage on Benitec Biopharma in a research note on Tuesday, May 12th. They issued an "outperform" rating and a $25.00 target price for the company. Guggenheim cut Benitec Biopharma from a "buy" rating to a "neutral" rating in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Benitec Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Benitec Biopharma in a report on Friday, July 17th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $24.80. **Check Out Our Latest Stock Report on BNTC** ## Benitec Biopharma Stock Performance The company has a market capitalization of $442.43 million, a price-to-earnings ratio of -11.30 and a beta of 0.28. The company has a 50-day moving average price of $12.48 and a 200-day moving average price of $11.88. ## Hedge Funds Weigh In On Benitec Biopharma Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in shares of Benitec Biopharma by 44.5% in the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after buying an additional 904 shares during the period. Truvestments Capital LLC lifted its position in Benitec Biopharma by 156.5% in the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 2,339 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Benitec Biopharma in the 3rd quarter worth $79,000. JPMorgan Chase & Co. bought a new position in Benitec Biopharma during the 2nd quarter worth about $80,000. Finally, Bank of America Corp DE raised its stake in shares of Benitec Biopharma by 2,255.8% in the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 6,587 shares during the period. 52.19% of the stock is currently owned by institutional investors and hedge funds. ## About Benitec Biopharma (Get Free Report) Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration. Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions. ## Read More - Five stocks we like better than Benitec Biopharma - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Benitec Biopharma Right Now? Before you consider Benitec Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list. While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BNTC.US](https://longbridge.com/en/quote/BNTC.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [EVR.US](https://longbridge.com/en/quote/EVR.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [WEN.US](https://longbridge.com/en/quote/WEN.US.md) - [HD.US](https://longbridge.com/en/quote/HD.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/296672427.md) - [Argyle Capital Partners LLC Purchases Shares of 9,375 Bank of America Corporation $BAC](https://longbridge.com/en/news/296675010.md) - [Meeder Advisory Services Inc. Invests $8.19 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296678230.md) - [Bank of America tops 10% stake in Lakefront Biotherapeutics voting rights disclosure](https://longbridge.com/en/news/296823581.md) - [Kesler Norman & Wride LLC Makes New Investment in Bank of America Corporation $BAC](https://longbridge.com/en/news/296080944.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**